TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
Rhea-AI Summary
Sabio (TSXV: SBIO / OTCQB: SABOF) announced a strategic content partnership between its Creator Television network and MADCOOL Media to produce scripted and unscripted series across genres with a focus on diverse creators.
Original series will be distributed on Creator Television via Xumo Play, Amazon Fire TV Channels, Sling Freestream, Plex, and LiveTVx, with combined reach of over 65 million viewers globally. The collaboration aims to expand creator-led programming and advertiser-facing inventory while advancing representation in television.
Positive
- Distribution reach of over 65 million viewers globally
- Signed partnership to produce original scripted and unscripted series
- Distribution across Xumo Play, Amazon Fire TV Channels, Sling Freestream, Plex, LiveTVx
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
HURA was up about 2.06% with below-average volume, while select biotech peers in scanners such as IOBT and INO were also up around 5.10% and 4.31% respectively, but overall sector moves were mixed, indicating a stock-specific backdrop rather than a clear sector-wide rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Q3 earnings update | Negative | +0.5% | Larger quarterly loss, liquidity risk, and higher R&D spending disclosed. |
| Nov 03 | Scientific presentation | Positive | -0.4% | Positive ASH 2025 DOR data and multiple presentations announced. |
| Aug 20 | Conference participation | Neutral | -0.7% | Participation in H.C. Wainwright conference and corporate overview. |
| Aug 14 | Q2 earnings update | Positive | +10.9% | Kineta acquisition, Phase 3 initiation, and new equity financing detailed. |
| Jul 01 | Index inclusion | Positive | +10.8% | Addition to Russell 3000® and 2000® indexes and trial progress noted. |
HURA has shown mixed reactions to news: positive moves on index inclusion and earlier earnings/financing updates, but divergence where shares rose slightly despite negative liquidity commentary and fell on otherwise positive scientific updates.
Over the last six months, TuHURA advanced its profile as a Phase 3 immuno-oncology company while actively managing its balance sheet. It completed the Kineta acquisition and highlighted IFx-2.0’s Phase 3 trial and future Phase 2 plans for TBS-2025. The company secured a $12.5M equity financing plus $3M from warrant exercises and later discussed liquidity risk and higher R&D spend in Q3 2025. Inclusion in the Russell 3000®/2000® and multiple conference and ASH presentations underscored growing visibility, against which the new offering adds another capital-raising step.
Regulatory & Risk Context
TuHURA has an active mixed Form S-3 shelf filed on 2025-11-03, registering up to $250,000,000 of securities plus 9,321,545 resale shares. The shelf also includes an ATM component of up to $50,000,000 of common stock. This structure allows the company to conduct primary offerings, like the newly announced registered direct, and at-the-market sales over time for working capital and program funding.
Market Pulse Summary
This announcement adds another financing step to TuHURA’s existing capital framework, which already includes a $250,000,000 mixed shelf and a $50,000,000 ATM program. The $15.6 million registered direct offering increases flexibility to fund the Phase 3 IFx-2.0 program and other pipeline work, but also introduces additional dilution on a stock trading below its 200-day moving average and far under its 52-week high. Monitoring future use of the shelf and clinical milestones remains important.
Key Terms
registered direct offering financial
free ad-supported streaming television (FAST) technical
AI-generated analysis. Not financial advice.
H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering. Rodman & Renshaw LLC is acting as co-placement agent for the offering.
The closing of the offering is expected to occur in three tranches. The first closing of the offering is expected to occur on or about December 10, 2025, subject to satisfaction of customary closing conditions. At the first closing, the Company will issue an aggregate of 5,219,999 shares of its common stock, Series A warrants to purchase up to an aggregate of 5,219,999 shares of its common stock and Series B warrants to purchase up to an aggregate of 5,219,999 shares of its common stock. The second closing of the offering is expected to occur by no later than January 30, 2026. At the second closing, the Company will issue an aggregate of 3,030,303 shares of its common stock, Series A warrants to purchase up to an aggregate of 3,030,303 shares of its common stock and Series B warrants to purchase up to an aggregate of 3,030,303 shares of its common stock. The third closing of the offering is expected to occur by no later than February 27, 2026. At the third closing, the Company will issue an aggregate of 1,212,121 shares of its common stock, Series A warrants to purchase up to an aggregate of 1,212,121 shares of its common stock and Series B warrants to purchase up to an aggregate of 1,212,121 shares of its common stock. The Series A warrants will expire five and one-half years from the date of the first closing and the Series B warrants will expire twenty-four months from the date of the first closing.
The gross proceeds to the Company are expected to be approximately
The securities described above are being offered pursuant to a "shelf" registration statement (File No. 333-291239) filed with the Securities and Exchange Commission ("SEC") on November 3, 2025, which became effective automatically on November 22, 2025. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC and be available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in its merger with Kineta Inc. on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to express or implied statements regarding TuHURA's expectations, hopes, beliefs, intentions or strategies regarding the future and include, without limitation, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ fmaterially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on the combined company's website, and at www.sec.gov.
The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
FAQ
What did Sabio (SBIO) announce on Sept. 22, 2025 regarding Creator Television?
How many viewers can Sabio's Creator Television (SBIO) reach after the MADCOOL partnership?
Which platforms will carry Sabio Creator Television (SBIO) content after the deal?
What types of shows will Sabio (SBIO) and MADCOOL produce together?
How does the partnership between Sabio (SBIO) and MADCOOL affect advertisers?
Who leads MADCOOL Media in the Sabio (SBIO) partnership announced Sept. 22, 2025?
